Interplay between AMA1 immunisation and parasite challenge leads to protection against malaria infection in rhesus macaques
© Hamid et al; licensee BioMed Central Ltd. 2010
Published: 20 October 2010
PkAMA1 monkeys produced antibodies that inhibited Pk growth in vitro. Monkeys were challenged two weeks after the third vaccination with Pk blood stage parasites and parasitaemia was followed for 3 weeks. Five out of six controls and one PkAMA1 animal developed fulminent parasitaemias. Four out of six PkAMA1 vaccinated monkeys delayed the onset of the parasitaemia (> 2 days) and one animal in the PkAMA1 group was able to completely control parasitaemia, which correlated with the level of parasite growth inhibitory antibodies. PkAMA1 vaccination delayed the rate of parasite development, but no apparent sterile protection was achieved (Figure 1).
Protection from Pk challenge is possible albeit non-sterilising. GIA correlates with protection, IgG levels do not at first challenge. Protection improves after challenge-boost. The findings presented here may have implications for Pf challenge models in humans.
- Cox-Singh J, Singh B: Knowlesi malaria: newly emergent and of public health importance?. Trends Parasitol. 2008, 24 (9): 406-10. 10.1016/j.pt.2008.06.001.PubMed CentralView ArticlePubMedGoogle Scholar
- Hilgers LA, Blom AG: Sucrose fatty acid sulphate esters as novel vaccine adjuvant. Vaccine. 2006, 12 (24 Suppl 2:S2): 81-2. 10.1016/j.vaccine.2005.01.133.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.